touchENDOCRINOLOGY were delighted to speak with Prof. Hiddo Lambers Heerspink to hear more about the highly anticipated results of DAPA-CKD, investigating dapagliflozin in patients with chronic kidney disease with or without type 2 diabetes.
Disclosures: Prof. Lambers Heerspink discloses the following: Grant Funding and Consultancy from AstraZeneca, Boehringer Ingelheim and AbbVie, Steering committee member for Bayer and Chinook, Advisory Board for Mundipharma and Merck, Advisory Board and Speaker for Mitsubishi Tanabe, Steering committee member and Advisory Board for Janssen, Steering committee member for Gilead and CSL Pharma and Consultancy for Retrophin and Novo Nordisk.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the European Association for the Study of Diabetes (EASD) 2020.
Share this Video
Related Videos In Diabetes
Clipper Young & Shirley Wong, ADCES 2022: New horizons in type 2 diabetes management and cardiorenal risk reduction: A pharmacotherapeutic update
Cardiorenal complications in people with type 2 diabetes illustrates a link between the heart and the kidneys, which can be exacerbated by other comorbidities, such as hypertension, dyslipidaemia, and obesity. In this touchENDOCRINOLOGY interview, Dr Clipper Young and Shirley Wong (Touro University California College of Osteopathic Medicine, Vallejo, CA, USA) firstly discuss diabetes management and […]
Jennifer Clements, ADCES 2022: Efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients with diabetes
In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss a study investigating the efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients. The abstract entitled: ‘A Retrospective Analysis of Once-daily versus Twice-daily Dosing of Insulin Glargine in Non-critically Ill […]
Jennifer Clements, ADCES 2022: Clinical implications of SGLT-2 inhibitors for chronic kidney disease in people with type 2 diabetes
Chronic kidney disease in people with type 2 diabetes is heavily prevalent, and the main causes are diabetes and hypertension. In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss the health burden of chronic kidney disease (CKD) in people with type 2 diabetes, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!